Condition
    Moderate Evidence
    Effectiveness 3/5

    Creatine Monohydrate for Depression

    Creatine is being studied as an adjunct to antidepressants, with the most striking results in women. It is not a standalone treatment, but as an add-on it has better evidence than most supplements marketed for mood.

    Overview

    The most striking evidence here is a randomised, double-blind, placebo-controlled trial in the American Journal of Psychiatry testing oral creatine monohydrate as augmentation to an SSRI in women with major depressive disorder. Adding creatine improved response beyond the antidepressant alone. Augmentation is the key word: this was creatine alongside treatment, not instead of it.
    A 2018 Experimental Gerontology review of creatine supplementation and brain health situates that finding in a wider literature on cerebral bioenergetics, where reduced brain phosphocreatine has been reported in depression. The evidence base remains small, the strongest trial was in women specifically, and sex differences in response have been noted. Treat creatine as a low-risk, low-cost adjunct worth discussing with a prescriber, not as an antidepressant.

    How It Works

    Depression has a recognised bioenergetic dimension. Phosphorus magnetic resonance spectroscopy studies have found reduced phosphocreatine and altered high-energy phosphate metabolism in the brains of depressed patients, particularly in frontal regions. Creatine supplementation raises brain phosphocreatine, which is the direct rationale for testing it as an augmentation agent.
    Secondary mechanisms have been proposed. Creatine influences mitochondrial function and may reduce oxidative stress in neural tissue, both implicated in depression pathophysiology. Interactions with monoamine systems have also been suggested in preclinical work, potentially explaining the synergy with SSRIs rather than a purely additive effect. Sex differences in response may relate to oestrogen effects on creatine kinase and on brain creatine transport, though this remains hypothesis rather than established fact.

    Dosing & Protocol

    The augmentation trial used 5 g per day of creatine monohydrate alongside an SSRI, continued for eight weeks. That is the best-supported regimen. Dosing is straightforward: 5 g daily, any time, taken consistently. Loading is unnecessary for a brain endpoint. Allow at least four weeks and assess at eight, alongside whatever formal monitoring of mood your clinician uses. Continue prescribed treatment unchanged.

    Adjunct only, never a replacement

    Do not stop or reduce prescribed antidepressants to try creatine. Any change to treatment should be made with your prescriber.

    Evidence

    Two linked sources support this pairing: a 2012 American Journal of Psychiatry randomised, double-blind, placebo-controlled trial of creatine monohydrate augmentation of an SSRI in women with major depressive disorder, and a 2018 Experimental Gerontology review of creatine supplementation and brain health. The trial is the direct evidence and is methodologically sound but small and restricted to women. The review provides the bioenergetic context rather than additional clinical outcome data.

    Studies linked to this pairing.

    Creatine Supplementation and Brain Health

    Score: 7/10
    2018

    Avgerinos KI, Spyrou N, Bougioukas KI +1 more

    Creatine supplementation and brain health.

    View source

    A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder

    Score: 7/10
    2012
    rct
    n=52

    Lyoo IK, Yoon S, Kim TS +5 more

    The creatine augmentation group showed significantly greater improvement in depression scores and higher remission rates than placebo.

    View source

    Safety

    Creatine has an excellent long-term safety record, with controlled use to five years showing no renal or hepatic harm in people with normal organ function. Water retention of one to two kilograms is intracellular and expected; gastrointestinal upset relates to large single doses. One psychiatric caution matters: isolated case reports describe mania or hypomania induced by creatine in people with bipolar disorder, so it should not be used there without specialist advice.

    Seek help urgently for suicidal thoughts

    Thoughts of self-harm or suicide need immediate professional support. Contact your doctor, a crisis line or emergency services rather than managing alone.

    Interactions & Conflicts

    Creatine has no established pharmacokinetic interactions with antidepressants; the trial evidence involves deliberate co-administration with an SSRI. The important conflicts are clinical rather than chemical: bipolar disorder, where creatine has been linked to switch into mania in case reports, and existing kidney disease, where trials have excluded participants and creatinine interpretation becomes unreliable.
    Interacts withSeverityMechanismAction
    high
    		——
    low
    		——
    moderate
    		——
    moderate
    		——
    high
    		——

    References

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.